Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:ENGN NASDAQ:QURE NASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.00-4.2%$3.48$1.24▼$4.08$795.44M1.024.17 million shs3.22 million shsENGNenGene$5.55+2.2%$3.95$2.65▼$11.00$283.61M-0.498,406 shs62,938 shsQUREuniQure$17.49+0.3%$15.05$4.45▼$19.18$959.62M0.131.35 million shs819,850 shsSANASana Biotechnology$3.02+0.7%$3.71$1.26▼$7.30$718.19M1.885.80 million shs2.08 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+5.74%-0.32%-8.48%-20.15%+131.85%ENGNenGene+4.83%+17.53%+47.55%+69.16%-17.85%QUREuniQure-2.90%+6.74%+31.25%+6.67%+221.59%SANASana Biotechnology+1.35%-1.96%0.00%+3.09%-40.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.00-4.2%$3.48$1.24▼$4.08$795.44M1.024.17 million shs3.22 million shsENGNenGene$5.55+2.2%$3.95$2.65▼$11.00$283.61M-0.498,406 shs62,938 shsQUREuniQure$17.49+0.3%$15.05$4.45▼$19.18$959.62M0.131.35 million shs819,850 shsSANASana Biotechnology$3.02+0.7%$3.71$1.26▼$7.30$718.19M1.885.80 million shs2.08 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+5.74%-0.32%-8.48%-20.15%+131.85%ENGNenGene+4.83%+17.53%+47.55%+69.16%-17.85%QUREuniQure-2.90%+6.74%+31.25%+6.67%+221.59%SANASana Biotechnology+1.35%-1.96%0.00%+3.09%-40.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.00Buy$6.75125.00% UpsideENGNenGene 3.00Buy$23.29319.56% UpsideQUREuniQure 3.00Buy$37.45114.15% UpsideSANASana Biotechnology 3.00Buy$8.00164.90% UpsideCurrent Analyst Ratings BreakdownLatest ENGN, QURE, SANA, and AKBA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.009/8/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.009/5/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.008/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/14/2025QUREuniQureMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$30.008/13/2025AKBAAkebia TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/30/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$47.007/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $35.007/3/2025SANASana BiotechnologyMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.006/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$5.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$203.73M3.90N/AN/A($0.23) per share-13.04ENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AQUREuniQure$14.34M66.93N/AN/A($0.14) per share-124.93SANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)ENGNenGene-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%9/10/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)SANASana Biotechnology-$266.76M-$1.06N/AN/AN/AN/A-91.96%-43.07%11/14/2025 (Estimated)Latest ENGN, QURE, SANA, and AKBA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025Q3 2025ENGNenGene-$0.5084N/AN/AN/AN/AN/A8/11/2025Q2 2025SANASana Biotechnology-$0.20-$0.16+$0.04-$0.39N/AN/A7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 million6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84ENGNenGene0.0912.6612.66QUREuniQure1.539.989.98SANASana BiotechnologyN/A2.472.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ENGNenGene64.16%QUREuniQure78.83%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ENGNenGene10.40%QUREuniQure4.79%SANASana Biotechnology31.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.15 million257.19 millionOptionableENGNenGene3151.10 million45.79 millionN/AQUREuniQure50054.87 million52.24 millionOptionableSANASana Biotechnology380237.81 million163.85 millionOptionableENGN, QURE, SANA, and AKBA HeadlinesRecent News About These CompaniesIeq Capital LLC Has $176,000 Position in Sana Biotechnology, Inc. $SANASeptember 9 at 3:32 AM | marketbeat.comInvesco Ltd. Purchases 117,144 Shares of Sana Biotechnology, Inc. $SANASeptember 9 at 3:08 AM | marketbeat.comSana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8 at 5:35 PM | seekingalpha.comJMP Securities Keeps Market Outperform Rating on Sana Biotechnology (SANA)September 8 at 2:51 AM | insidermonkey.comBrokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Price Target at $8.00September 8 at 2:18 AM | americanbankingnews.comTop 10 Stocks Under $10 That Could TripleSeptember 7 at 4:52 PM | insidermonkey.comSana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Buy" by AnalystsSeptember 7 at 5:11 AM | marketbeat.comHope for diabetes: CRISPR-edited cells pump out insulin in a person – and evade immune detectionSeptember 6 at 12:10 PM | nature.comNRafferty Asset Management LLC Has $328,000 Position in Sana Biotechnology, Inc. $SANASeptember 6 at 4:35 AM | marketbeat.com350,539 Shares in Sana Biotechnology, Inc. $SANA Bought by Nuveen LLCSeptember 6 at 3:28 AM | marketbeat.comSana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comSana Biotechnology, Inc. $SANA Shares Sold by Baker BROS. Advisors LPSeptember 4, 2025 | marketbeat.comSana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comSana Biotechnology Announces Public Offering PricingAugust 28, 2025 | theglobeandmail.comSana Biotechnology to Present at September 2025 Investor ConferencesAugust 26, 2025 | globenewswire.comDeutsche Bank AG Has $1.12 Million Stock Holdings in Sana Biotechnology, Inc. $SANAAugust 26, 2025 | marketbeat.comCitizens JMP Reiterates a Buy Rating on Sana Biotechnology (SANA) With a $5 PTAugust 25, 2025 | msn.comBiotech’s Big Bang: IPOs, Uplists, and the Short Squeeze EffectAugust 21, 2025 | msn.comSana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional SharesAugust 21, 2025 | uk.finance.yahoo.comSana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase ...August 21, 2025 | bakersfield.comBSana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional SharesAugust 20, 2025 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENGN, QURE, SANA, and AKBA Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.00 -0.13 (-4.15%) Closing price 04:00 PM EasternExtended Trading$2.98 -0.02 (-0.50%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.enGene NASDAQ:ENGN$5.55 +0.12 (+2.21%) Closing price 04:00 PM EasternExtended Trading$5.56 +0.02 (+0.27%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.uniQure NASDAQ:QURE$17.49 +0.06 (+0.34%) Closing price 04:00 PM EasternExtended Trading$17.32 -0.16 (-0.94%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Sana Biotechnology NASDAQ:SANA$3.02 +0.02 (+0.67%) Closing price 04:00 PM EasternExtended Trading$3.00 -0.02 (-0.83%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 What August Labor Data Means for the S&P 500 in September Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
